Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
AssigneesCenter for Innovative Technology, Virginia Commonwealth University
InventorsPeter R. Byron, Frank E. Blondino
Life of this patent
Estimating the term…
Abstract
Metered dose inhaler (MDI) formulations which utilize 1,1,1,2-tetrafluoroethane (HFC 134a) as the sole propellant are made practical by including a polar surfactant such as polyethylene glycol, diethylene glycol monoethyl ether, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, propoxylated polyethylene glycol, and polyoxyethylene (4) lauryl ether for suspending, solubilizing, wetting and emulsifying the drug constituent and lubricating the valve components of the MDI.
Claims7
An aerosol formulation for use in a metered dose inhaler, consisting essentially of:
- greater than 90% by weight of 1,1,1,2-tetrafluoroethane, said 1,1,1,2-tetrafluoroethane being the sole propellant and excipient which is not a surfactant in the aerosol formulation;
- less than 5% by weight of micronized drug particles;
- and
- less than 5% by weight of a polar surfactant selected from the group consisting of polyethylene glycol 300, diethylene glycol monoethyl ether, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 20 sorbitan monooleate, propoxylated polyethylene glycol, and polyoxyethylene 4 lauryl ether.
Dependencies are inferred from the claim text.